Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13307598 | 0.96 | CNR1 (0.52) | POLBMAPTCNR1CYP19A1L3MBTL1 | |
| SCHEMBL13307565 | 0.93 | POLB (0.58) | POLBMAPTGAAL3MBTL1MEN1 | |
| SCHEMBL13307611 | 0.92 | CNR1 (0.48) | POLBMAPTCNR1CYP19A1MEN1 | |
| SCHEMBL13307627 | 0.91 | CNR1 (0.47) | POLBMAPTCNR1CYP19A1MEN1 | |
| SCHEMBL13307625 | 0.91 | CNR1 (0.47) | POLBMAPTCNR1CYP19A1MEN1 | |
| SCHEMBL13307629 | 0.91 | CNR1 (0.47) | POLBMAPTCNR1CYP19A1MEN1 | |
| SCHEMBL13307646 | 0.90 | POLB (0.53) | POLBMAPTCYP19A1GAAL3MBTL1 | |
| SCHEMBL13307632 | 0.89 | MAPT (0.55) | POLBMAPTGAAL3MBTL1MEN1 | |
| SCHEMBL13307634 | 0.89 | HSP90AA1 (0.46) | MAPTCNR1CYP19A1L3MBTL1NPSR1 | |
| SCHEMBL13307654 | 0.87 | POLB (0.50) | POLBMAPTGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | CNR1, CNR2, GPR3 | POLB 4840/4885MAPT 2428/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.